Marine animal biosynthetic constituents for cancer chemotherapy

George R. Pettit, Yoshiaki Kamano, Youichi Fujii, Cherry L. Herald, Masuo Inoue, Peter Brown, John Devens Gust, Keiichi Kitahara, Jean M. Schmidt, Dennis L. Doubek, Claude Michel

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

A fifteen year investigation of marine animal components as sources for new and potentially useful cancer chemotherapeutic drugs has led to our discovery of a number of such valuable substances. The especially productive Indian Ocean sea hare Dolabella auricularia has yielded (100 kg→∼1 mg each) a series of very potent cell growth inhibitory substances designated dolastatins 1-9. The first member of this new series, dolastatin 1, may represent the most potent anticancer agent so far uncovered with, e.g., a curative response (33%) using a dose of 11 μg/kg (T/C 240, to T/C 139 at 1.37 μg/kg) in the National Cancer Institute's murine B16 melanoma. Structural elucidation of the new antineoplastic agents is underway, and recent progress is illustrated with the peptide dolastatin 3 (P388 ED50 2.7 ×10-7 μg/ml).

Original languageEnglish
Pages (from-to)482-485
Number of pages4
JournalJournal of Natural Products
Volume44
Issue number4
Publication statusPublished - 1981

Fingerprint

Chemotherapy
antineoplastic agents
Antineoplastic Agents
drug therapy
Animals
Growth Substances
Hares
Indian Ocean
Drug Therapy
Experimental Melanomas
neoplasms
National Cancer Institute (U.S.)
Cell growth
melanoma
Oceans and Seas
cell growth
Neoplasms
animals
peptides
drugs

ASJC Scopus subject areas

  • Plant Science
  • Chemistry (miscellaneous)
  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Pettit, G. R., Kamano, Y., Fujii, Y., Herald, C. L., Inoue, M., Brown, P., ... Michel, C. (1981). Marine animal biosynthetic constituents for cancer chemotherapy. Journal of Natural Products, 44(4), 482-485.

Marine animal biosynthetic constituents for cancer chemotherapy. / Pettit, George R.; Kamano, Yoshiaki; Fujii, Youichi; Herald, Cherry L.; Inoue, Masuo; Brown, Peter; Gust, John Devens; Kitahara, Keiichi; Schmidt, Jean M.; Doubek, Dennis L.; Michel, Claude.

In: Journal of Natural Products, Vol. 44, No. 4, 1981, p. 482-485.

Research output: Contribution to journalArticle

Pettit, GR, Kamano, Y, Fujii, Y, Herald, CL, Inoue, M, Brown, P, Gust, JD, Kitahara, K, Schmidt, JM, Doubek, DL & Michel, C 1981, 'Marine animal biosynthetic constituents for cancer chemotherapy', Journal of Natural Products, vol. 44, no. 4, pp. 482-485.
Pettit GR, Kamano Y, Fujii Y, Herald CL, Inoue M, Brown P et al. Marine animal biosynthetic constituents for cancer chemotherapy. Journal of Natural Products. 1981;44(4):482-485.
Pettit, George R. ; Kamano, Yoshiaki ; Fujii, Youichi ; Herald, Cherry L. ; Inoue, Masuo ; Brown, Peter ; Gust, John Devens ; Kitahara, Keiichi ; Schmidt, Jean M. ; Doubek, Dennis L. ; Michel, Claude. / Marine animal biosynthetic constituents for cancer chemotherapy. In: Journal of Natural Products. 1981 ; Vol. 44, No. 4. pp. 482-485.
@article{c59a9f94bbcf4a0fac38e6503f983641,
title = "Marine animal biosynthetic constituents for cancer chemotherapy",
abstract = "A fifteen year investigation of marine animal components as sources for new and potentially useful cancer chemotherapeutic drugs has led to our discovery of a number of such valuable substances. The especially productive Indian Ocean sea hare Dolabella auricularia has yielded (100 kg→∼1 mg each) a series of very potent cell growth inhibitory substances designated dolastatins 1-9. The first member of this new series, dolastatin 1, may represent the most potent anticancer agent so far uncovered with, e.g., a curative response (33{\%}) using a dose of 11 μg/kg (T/C 240, to T/C 139 at 1.37 μg/kg) in the National Cancer Institute's murine B16 melanoma. Structural elucidation of the new antineoplastic agents is underway, and recent progress is illustrated with the peptide dolastatin 3 (P388 ED50 2.7 ×10-7 μg/ml).",
author = "Pettit, {George R.} and Yoshiaki Kamano and Youichi Fujii and Herald, {Cherry L.} and Masuo Inoue and Peter Brown and Gust, {John Devens} and Keiichi Kitahara and Schmidt, {Jean M.} and Doubek, {Dennis L.} and Claude Michel",
year = "1981",
language = "English",
volume = "44",
pages = "482--485",
journal = "Journal of Natural Products",
issn = "0163-3864",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Marine animal biosynthetic constituents for cancer chemotherapy

AU - Pettit, George R.

AU - Kamano, Yoshiaki

AU - Fujii, Youichi

AU - Herald, Cherry L.

AU - Inoue, Masuo

AU - Brown, Peter

AU - Gust, John Devens

AU - Kitahara, Keiichi

AU - Schmidt, Jean M.

AU - Doubek, Dennis L.

AU - Michel, Claude

PY - 1981

Y1 - 1981

N2 - A fifteen year investigation of marine animal components as sources for new and potentially useful cancer chemotherapeutic drugs has led to our discovery of a number of such valuable substances. The especially productive Indian Ocean sea hare Dolabella auricularia has yielded (100 kg→∼1 mg each) a series of very potent cell growth inhibitory substances designated dolastatins 1-9. The first member of this new series, dolastatin 1, may represent the most potent anticancer agent so far uncovered with, e.g., a curative response (33%) using a dose of 11 μg/kg (T/C 240, to T/C 139 at 1.37 μg/kg) in the National Cancer Institute's murine B16 melanoma. Structural elucidation of the new antineoplastic agents is underway, and recent progress is illustrated with the peptide dolastatin 3 (P388 ED50 2.7 ×10-7 μg/ml).

AB - A fifteen year investigation of marine animal components as sources for new and potentially useful cancer chemotherapeutic drugs has led to our discovery of a number of such valuable substances. The especially productive Indian Ocean sea hare Dolabella auricularia has yielded (100 kg→∼1 mg each) a series of very potent cell growth inhibitory substances designated dolastatins 1-9. The first member of this new series, dolastatin 1, may represent the most potent anticancer agent so far uncovered with, e.g., a curative response (33%) using a dose of 11 μg/kg (T/C 240, to T/C 139 at 1.37 μg/kg) in the National Cancer Institute's murine B16 melanoma. Structural elucidation of the new antineoplastic agents is underway, and recent progress is illustrated with the peptide dolastatin 3 (P388 ED50 2.7 ×10-7 μg/ml).

UR - http://www.scopus.com/inward/record.url?scp=0019846016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019846016&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 482

EP - 485

JO - Journal of Natural Products

JF - Journal of Natural Products

SN - 0163-3864

IS - 4

ER -